Ide-Cel Shows Benefit vs Standard Regimens in Heavily Pretreated R/R Multiple MyelomaMarch 30th 2023
Idecabtagene vicleucel (ide-cel) led to significantly longer PFS and better therapy responses than standard regimens for patients with triple-class–exposed relapsed and refractory multiple myeloma.
Prurigo Nodularis Improves Following Treatment With DupilumabMarch 30th 2023
Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the monoclonal antibody for the chronic inflammatory skin condition.
Bridging the Gap in Health Care Inequities: Considerations in Treatment Selection: Part 1March 30th 2023
In part 1 of this 2-part series on health equity in the treatment of psoriasis, Ryan Haumschild, PharmD, and Bryan Buckley, DrPH, discuss how providers can address disparities in care, specifically with race, cultural, and ethnic backgrounds in mind.
What We’re Reading: Health Insurers to Cut PA Process; Bipartisan Bill to Stop MA Overpayments; J&J Ends RSV Vaccine WorkMarch 30th 2023
Payers are looking to roll back on paperwork requirements for prior authorization (PA); CMS and Medicare Advantage (MA) insurers battle over new regulations; Johnson & Johnson (J&J) falls behind Pfizer and GSK for vaccine approval.
Immunotherapy for NSCLC Safe in Elderly Patients, but More Research NeededMarch 30th 2023
A review based on an expert panel discussion highlights a need for the inclusion of older patients in studies of immune checkpoint inhibitors for the first-line treatment of advanced non–small cell lung cancer (NSCLC).
Pembrolizumab Receives Full Approval for Select Patients With MSI-H or dMMR Solid Tumors
The FDA has granted full approval to pembrolizumab for the treatment of some patients with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors that have progressed following previous treatment.
CVD Outcomes Investigation Highlights Need for More, Better Data on SDOHMarch 29th 2023
This study of the public health landscape in New York City investigated the interplay between social determinants of health (SDOH), chronic health conditions, and inequities in social factors, with a focus on cardiovascular disease (CVD).
High Levels of RSV Linked With Respiratory Infections Detected Right Before the PandemicMarch 29th 2023
The incidence of respiratory syncytial virus (RSV)–positive acute respiratory infection (ARI) was found to be significant in the period prior to the COVID-19 pandemic in older adults.
What We’re Reading: FDA Approves OTC Naloxone; Obesity Drugs Might Be “Essential” by WHO; WHO Revamps COVID-19 Vaccine RecsMarch 29th 2023
The FDA approves over-the-counter (OTC) naloxone that will be available in late summer; the World Health Organization (WHO) might consider obesity drugs “essential” in upcoming review; the WHO updates COVID-19 vaccine recommendations.
What We’re Reading: 10 States Recalcitrant on Medicaid; FDA Aware of Formula Issue Before Recall; Senator Wants AmeriSourceBergen ProbeMarch 28th 2023
Ten states remain that have not expanded Medicaid and they are unlikely to do so; FDA was aware of contaminated infant formula months before the most recent recall; Sen. Tammy Duckworth asks the Federal Trade Commission to investigate AmeriSourceBergen over its distribution practices around the brand-name of mifepristone (Mifeprex).
Challenges in Standardizing Use of MRD Assessment in CLLMarch 27th 2023
Although minimal residual disease (MRD) has emerged as a valuable prognostic marker across several hematological malignancies, its use in chronic lymphocytic leukemia (CLL) is mostly limited to clinical trials.